5 Topic Commentaries

Clinical Trial Update September/October 2026

• 

  Tiffany Traina, MD

  Breast medical oncology

  •

  Memorial Sloan Kettering Cancer Center

  “Dato-DXd significantly improved overall survival for this challenging subtype of breast cancer, where historic median overall survival has been about 12 months,”

  Source
• 

  Ghassan Abou-Alfa, MD, JD, MBA, PhD(hc)

  Gastrointestinal medical oncology (liver cancer)

  •

  Memorial Sloan Kettering Cancer Center

  “These data represent a crucial step forward in a disease where progress has been limited,”

  Source
• 

  Elizabeth Jaffee, M.D.

  Medical oncology; cancer immunotherapy; pancreatic cancer

  •

  Johns Hopkins Medicine

  “This is just the beginning, but the findings suggest that the immune system is getting activated,”

  Source
• 

  Jenni Sheng, M.D.

  Medical oncology; survivorship and supportive care

  •

  Johns Hopkins Medicine

  “Our study suggests we don’t have to take a one-size-fits-all approach.”

  Source
• 

  Mark Tyson II, M.D.

  Urology; bladder cancer

  •

  Mayo Clinic (Arizona)

  “Until now, patients whose cancer returned after BCG therapy have had few effective options besides bladder removal,”

  Source